Transfusion Independence Zepbound Memory Improvement Weight Loss Drugs Patient Outcomes Obesity Treatment Zepbound Studies Weight Loss Injections Best-in-Class Medicines
The deal, which could reach $2 billion with milestones, positions GSK to target unmet needs in liver disease with a planned 2029 launch.